When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Síndrome de Wiskott-Aldrich

Última revisão: 21 Oct 2024
Última atualização: 12 Apr 2022

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • história familiar de SWA
  • facilidade de formar hematomas e petéquias
Detalhes completos

Outros fatores diagnósticos

  • infecções recorrentes
  • eczema
  • hematomas e petéquias
  • linfadenopatia
  • membranas timpânicas perfuradas
  • sangramento grave
  • infecção grave/com risco de vida
  • autoimunidade
Detalhes completos

Fatores de risco

  • portador de mutação do gene WAS materno
  • sexo masculino
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • hemograma completo com volume plaquetário
  • análise da proteína WAS (WASp)
  • análise da mutação gênica da proteína WAS (WASp)
Detalhes completos

Investigações a serem consideradas

  • níveis de imunoglobulina
  • respostas à vacina
  • iso-hemaglutininas
  • subgrupos de linfócitos
  • ensaios de proliferação das células T
  • testes da função hepática
  • análise por reação em cadeia da polimerase para hepatite C
  • testes de reação em cadeia da polimerase para adenovírus, vírus Epstein-Barr e citomegalovírus
  • reservar soro e plasma
Detalhes completos

Algoritmo de tratamento

Contínua

síndrome de Wiskott-Aldrich (SWA) atenuada

síndrome de Wiskott-Aldrich (SWA) clássica grave

Colaboradores

Autores

Siobhan Burns, MB BAO BCh, MRCPI (Paeds)
Siobhan Burns

Reader and Consultant in Immunology

University College London

Department of Immunology

Royal Free Hospital

London

UK

Declarações

SB has received travel expenses for educational conferences from Baxalta US Inc. and CSL Behring. SB has received a consulting fee from CSL Behring for a talk given about the use of subcutaneous immunoglobulin. SB has received grant funding for research into immunoglobulin treatment for primary immunodeficiency from CSL Behring. SB is the author of articles cited in this topic.

Adrian Thrasher, PhD, MD, BS, FRCP, MRCPCH, FMedSci
Adrian Thrasher

Professor of Paediatric Immunology

Molecular Immunology Unit and Centre for Immunodeficiency

Institute of Child Health

University College London

London

UK

Declarações

AT has done consultancy work for Orchard Therapeutics and Autolus, and owns stock in both. AT was an expert witness for Ward Hadaway Solicitors for a case of Wiskott-Aldrich syndrome. He is an author of references cited in this topic.

Revisores

Phil Fischer, MD

Professor of Pediatrics

Mayo Clinic

Rochester

MN

Declarações

PF declares that he has no competing interests.

Deepak Kamat, MD, PhD

Professor of Pediatrics

Wayne State University

Vice Chair of Education

Director

Institute of Medical Education

The Carman and Ann Adams Department of Pediatrics

Children's Hospital of Michigan

Detroit

MI

Declarações

DK declares that he has no competing interests.

  • Síndrome de Wiskott-Aldrich images
  • Diagnósticos diferenciais

    • Trombocitopenia idiopática (TPI)
    • Síndrome linfoproliferativa autoimune (SLPA)
    Mais Diagnósticos diferenciais
  • Diretrizes

    • COVID-19 vaccines for moderately or severely immunocompromised people
    • EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity
    Mais Diretrizes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal